Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Oncol Res Treat. 2022;45(11):681-692. doi: 10.1159/000526481. Epub 2022 Aug 19.
Metronomic chemotherapy (MCT), termed sustained low-dose administration with minimal toxicity, is a new modality of conventional chemotherapy, a verified therapy alternative, and has acquired significant recognition and interest in oncology. Numerous clinical trials of MCT in combination with other treatments, including targeted therapies, biologics, and endocrine therapy, are in progress to obtain better results.
We comprehensively described the clinical benefits of MCT in combination with other treatments in different molecular subtypes of breast cancer and assessed the feasibility of its adoption in varying phases of treatment. Due to the promising preclinical and clinical investigations, it is expected that MCT in combination with other treatments will enhance the advantages of this strategy and apply it to clinical practice.
MCT, in combination with other therapeutic interventions, will fully exploit the benefits of this strategy, ushering in a new paradigm in oncology treatment and driving the transformation of cancer into a more manageable chronic disease using newly developed treatment approaches.
节拍化疗（MCT），也称为最小毒性的持续低剂量给药，是一种新的常规化疗方式，已被证实为一种可行的治疗选择，并在肿瘤学领域得到了广泛的认可和关注。目前正在进行许多 MCT 与其他治疗方法（包括靶向治疗、生物制剂和内分泌治疗）联合应用的临床试验，以期获得更好的效果。
我们全面描述了 MCT 联合其他治疗方法在不同分子亚型乳腺癌中的临床获益，并评估了其在不同治疗阶段应用的可行性。由于有前景的临床前和临床研究，预计 MCT 联合其他治疗方法将增强这种策略的优势，并将其应用于临床实践。
MCT 联合其他治疗干预措施，将充分发挥这种策略的优势，为肿瘤治疗带来新的范例，并通过新开发的治疗方法将癌症转变为更易于管理的慢性病。
